ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0582

Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults
Abstract Number: 0583

Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing
Abstract Number: 0584

High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
Abstract Number: 0585

Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
Abstract Number: 0586

Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study
Abstract Number: 0587

DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Abstract Number: 0588

Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Abstract Number: 0589

Circulating Adipokines and Risk of Rheumatoid Arthritis in Women
Abstract Number: 0590

Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
Abstract Number: 0591

The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Abstract Number: 0592

Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Abstract Number: 0593

Labour Force Participation Among Individuals with Osteoarthritis, Rheumatoid Arthritis/Other Arthritis Types, or with Joint Symptoms but Without a Diagnosis: An Age-Stratified Population-Based Study
Abstract Number: 0594

The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
Abstract Number: 0595

Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Abstract Number: 0596

Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].